All Releases
View Summary Celldex Therapeutics to Present Clinical Results at 2017 ASCO Annual Meeting
May 17, 2017
PDF 12.0 KB Add to Briefcase
View Summary Celldex Reports First Quarter 2017 Results
May 9, 2017
PDF 25.4 KB Add to Briefcase
View Summary Celldex Provides Corporate Update and Reports Full Year 2016 Results
Mar 14, 2017
PDF 28.2 KB Add to Briefcase
View Summary Celldex Therapeutics Announces Appointment to Board of Directors
Mar 1, 2017
PDF 12.2 KB Add to Briefcase
View Summary Celldex Therapeutics Announces Upcoming Investor Presentations and 2016 Year-End Call
Feb 13, 2017
PDF 12.6 KB Add to Briefcase
View Summary Celldex Therapeutics Announces Appointment to Board of Directors
Dec 14, 2016
PDF 12.7 KB Add to Briefcase
View Summary Theresa LaVallee, Ph.D., Joins Celldex Therapeutics' Senior Management Team
Dec 5, 2016
PDF 13.2 KB Add to Briefcase
View Summary Celldex Presents Data on CDX-1140, a Novel CD40 Agonist Antibody for Hematologic and Solid Malignancies, at the American Society of Hematology (ASH) Annual Meeting
Dec 5, 2016
PDF 18.1 KB Add to Briefcase
View Summary Celldex Therapeutics Completes Acquisition of Kolltan Pharmaceuticals
Nov 29, 2016
PDF 15.2 KB Add to Briefcase
View Summary Celldex Presents Data on New Product Candidate, CDX-1140, a Novel CD40 Agonist Antibody
Nov 14, 2016
PDF 15.6 KB Add to Briefcase
View Summary Celldex Reports Third Quarter 2016 Results
Nov 7, 2016
PDF 35.5 KB Add to Briefcase
View Summary Celldex Expands Antibody and Immuno-Oncology Portfolio with the Acquisition of Kolltan Pharmaceuticals
Nov 1, 2016
PDF 21.5 KB Add to Briefcase
View Summary Phase 2 Study of Single-agent Glembatumumab Vedotin in Patients with Checkpoint-Refractory Metastatic Melanoma Meets Primary Overall Response Endpoint and Demonstrates Clinically Meaningful Duration of Response
Oct 9, 2016
PDF 21.1 KB Add to Briefcase
View Summary Celldex Therapeutics to Present at the Leerink Partners Rare Disease & Immuno-Oncology Roundtable
Sep 23, 2016
PDF 9.5 KB Add to Briefcase
View Summary Celldex Appoints Elizabeth Crowley as Chief Product Development Officer
Aug 11, 2016
PDF 13.1 KB Add to Briefcase
View Summary Celldex Reports Second Quarter 2016 Results
Aug 8, 2016
PDF 34.9 KB Add to Briefcase
View Summary Celldex to Report Second Quarter 2016 Financial Results and Host Corporate 2016 Objectives Update Call
Aug 2, 2016
PDF 9.9 KB Add to Briefcase
View Summary Celldex Therapeutics Initiates Phase 1/2 Clinical Trial of New Product Candidate CDX-014 in Advanced Renal Cell Carcinoma
Jul 11, 2016
PDF 15.9 KB Add to Briefcase
View Summary Celldex Therapeutics to Participate in the Cantor Fitzgerald 2nd Annual Healthcare Conference
Jul 7, 2016
PDF 9.4 KB Add to Briefcase
View Summary Celldex Therapeutics' CDX‑1401, CDX‑301 Combination Generates Potent NY-ESO-1 Immune Responses in Patients with Melanoma
Jun 4, 2016
PDF 17.7 KB Add to Briefcase
Showing 1-20 of 144 Page: 1 2 3 4 5 ... 8  Next 20
Showing 1-20 of 144
Page: 1 2 3 4 5 ... 8
 Next 20
Add to Briefcase = add release to Briefcase